AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23599046
Drug: D-Cycloserine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Cycloserine (50 mg before each of five exposure sessions)
Trial: 20648212
Drug: Lumbar intraarticular
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumbar intraarticular facet joint injections
Trial: 20648212
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural steroids for conditions other than disc herniation or radiculitis
Trial: 20648212
Drug: Sacroiliac joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacroiliac joint injections
Trial: 18164457
Drug: Intradiscal electrothermal
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal electrothermal therapy
Trial: 20648212
Drug: Intrathecal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal therapy
Trial: 20648212
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injections in disc herniation or radiculitis
Trial: 20648212
Drug: Transforaminal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal epidural injections in radiculitis
Trial: 17901215
Drug: Physician communication
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician communication behaviors (interactive conversation, short-term goals, criteria for decision making, long-term treatment plan, tailoring according to needs)
Trial: 10868720
Drug: Le Bon
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Le Bon Départ treatment
Trial: 10868720
Drug: Sensory Integration
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensory Integration treatment
Trial: 9106374
Drug: Nortriptyline for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline for 6 weeks (with possible adjunctive lithium)
Trial: 9106374
Drug: Phenelzine for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenelzine for 6 weeks (with possible lithium augmentation)
Trial: 9106374
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy or fluoxetine for 6 weeks (with possible lithium augmentation)
Trial: 3896663
Drug: Pivampicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin (500 mg or 1 g twice daily)
Trial: 3896663
Drug: Amoxycillin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (250 mg or 500 mg 3-times daily)
Trial: 26919833
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg/day) and Naoxintong Capsule (1.6 g thrice a day)
Trial: 26919833
Drug: Adjusted-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose warfarin (international normalized ratio 2.0-3.0)
Trial: 26919833
Drug: Aspirin combined
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin combined with NXT and warfarin
Trial: 27511181
Drug: Sirolimus treatment
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus treatment (titrated to trough levels of 5-10 ng/mL)
Trial: 27511181
Drug: Sirolimus treatment
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus treatment (for children who reached target trough levels)
Trial: 24652518
Drug: Ranibizumab or
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab or Bevacizumab treatment
Trial: 31754133
Drug: β-blockers (metoprolol)
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blockers (metoprolol)
Trial: 22972872
Drug: Pooled analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled analysis of β-blockers
Trial: 10411846
Drug: Primary stenting
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary stenting with the heparin‐coated Palmaz‐Schatz stent
Trial: 7738626
Drug: Dopamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine (2 micrograms/kg/min continuous infusion over 48 hours)
Trial: 1876891
Drug: Lidocaine (LID)
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine (LID) 2 mg/min constant-rate infusion after a bolus of LID 100 mg (Group A)
Trial: 1876891
Drug: Lidocaine (LID)
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine (LID) 2 mg/min constant-rate infusion after a bolus of LID 100 mg + Magnesium Sulfate (M) 2.5 mg/min (Group B)
Trial: 29955932
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1000 mg daily)
Trial: 25134291
Drug: GnRH analogues
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH analogues (subcutaneous triptorelin depot injection) before hydrothermal endometrial ablation (HTA)
Trial: 25134291
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no presurgical treatment)
Trial: 22481014
Drug: Curcuminoids 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids 4 g/day starting 3 days before surgery until 5 days after surgery
Trial: 19859699
Drug: Placebo (sorbitol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sorbitol) tablets
Trial: 19859699
Drug: Glucose tablets
RxNorm normalized name: Glucose Tablets Orange Obsolete
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose tablets with other medication (NRT/bupropion)
Trial: 19859699
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with other medication (NRT/bupropion)
Trial: 19859699
Drug: Glucose tablets
RxNorm normalized name: Glucose Tablets Orange Obsolete
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose tablets without other medication
Trial: 19859699
Drug: Placebo without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo without other medication
Trial: 16981901
Drug: Roflumilast (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast (500 microg once daily for 14 days)
Trial: 16981901
Drug: Midazolam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (2 mg oral and 1 mg i.v., 1 day apart)
Trial: 7485932
Drug: Previous oral
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous oral herpes
Trial: 369868
Drug: Paracetamol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1.0 g x 4 for 2 days, then 0.5 g x 4 for the next 2 days)
Trial: 24051231
Drug: Theanine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theanine (200 mg, twice a day, after breakfast and lunch)
Trial: 22151785
Drug: Garlic (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic (1200 μg allicin, three times daily)
Trial: 22151785
Drug: d‐penicillamine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐penicillamine (250 mg, three times daily)
Trial: 11593322
Drug: Weekly CMV
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly CMV antigenemia testing with ganciclovir administration for a positive result
Trial: 10186958
Drug: 2-minute treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-minute treatment of concentrated (5 mg/mL) albuterol in the Circulaire nebulizer
Trial: 10186958
Drug: Conventional unit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional unit dose treatment
Trial: 8115670
Drug: Haloperidol (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (10, 20 or 30 mg/day for three weeks)
Trial: 3398512
Drug: Walking at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walking at a pace that elicited 60% of V̇O2max, for 30 minutes, three times weekly for twelve weeks.
Trial: 29411268
Drug: Cysteamine Bitartrate
RxNorm normalized name: Cysteamine Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteamine Bitartrate Delayed-Release (CBDR) capsules with orange juice
Trial: 29411268
Drug: Cysteamine Bitartrate
RxNorm normalized name: Cysteamine Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteamine Bitartrate Delayed-Release (CBDR) capsules with water
Trial: 29411268
Drug: Cysteamine Bitartrate
RxNorm normalized name: Cysteamine Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteamine Bitartrate Delayed-Release (CBDR) capsules with omeprazole 20 mg and water
Trial: 29411268
Drug: Omeprazole co-administration
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole co-administration
Trial: 29411268
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (orange juice, water, omeprazole)
Trial: 19244630
Drug: Droperidol 5
RxNorm normalized name: droPERidol 5 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 5 mg IM
Trial: 19244630
Drug: Olanzapine 10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10 mg IM
Trial: 12622339
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of 0.65 g/kg alcohol and 4 mg/kg caffeine
Trial: 12622339
Drug: 0.65 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.65 g/kg alcohol alone
Trial: 12622339
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg caffeine alone
Trial: 8743003
Drug: 2% dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% dorzolamide thrice daily
Trial: 1889719
Drug: Ranitidine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 150 mg nightly (continuous dosing)
Trial: 1889719
Drug: Ranitidine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 150 mg nightly (intermittent dosing)
Trial: 1889719
Drug: Both intermittent
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both intermittent and continuous dosing with ranitidine
Trial: 6614662
Drug: Intravenous and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and/or oral potassium chloride supplementation during preoperative bowel preparation (60 mmol average supplementation)
Trial: 31335755
Drug: Ketamine/propofol admixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine/propofol admixture (0.5 mg/kg of ketamine and propofol each)
Trial: 1768820
Drug: Etomidate (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.15 mg/kg)
Trial: 27179770
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group (IV and topical TXA)
Trial: 766619
Drug: Placebo (sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sterile saline solution)
Trial: 22124602
Drug: Supervised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised physical therapy focusing on strengthening exercises of the rotator cuff and scapula stabilizers (PT-group)
Trial: 15223106
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol valerate 2 mg per day plus normegestrol acetate 2.5 mg per day for 12 months
Trial: 15223106
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (50 microg per day) plus normegestrol acetate 2.5 mg per day for 12 months
Trial: 9679581
Drug: UFT as
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT as adjuvant chemotherapy for bladder cancer (12 patients)
Trial: 9679581
Drug: UFT combined
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT combined with endocrine therapy for prostate cancer (10 patients)
Trial: 2529028
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of HPR
Trial: 2529028
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of HPR
Trial: 2529028
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of HPR
Trial: 1100225
Drug: NSC-122819 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSC-122819 (50 mg/m2/dose iv twice weekly for 4 weeks)
Trial: 1100225
Drug: NSC-141540 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSC-141540 (75 mg/m2/dose iv twice weekly for 4 weeks)
Trial: 23598288
Drug: Plasmalyte infusion
RxNorm normalized name: Plasmalyte A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmalyte infusion
Trial: 11181464
Drug: Ramipril 2.5
RxNorm normalized name: ramipril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 2.5 mg/d
Trial: 9835978
Drug: Continuous injection
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous injection (CA) group, n = 21
Trial: 8129127
Drug: Tonsillar infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonsillar infiltration with 0.25% bupivacaine administered after both tonsils had been surgically removed (n = 12)
Trial: 2916912
Drug: Usual athletic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual athletic and daily physical activities (Control group).
Trial: 4901344
Drug: Trimethoprim 320
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimethoprim 320 mg and Sulphamethoxazole 1,600 mg a day
Trial: 4901344
Drug: Ampicillin 2
RxNorm normalized name: ampicillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin 2 g a day
Trial: 19253204
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg q.d. and 50 mg b.i.d.
Trial: 16633143
Drug: Fluvoxamine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (150 mg/d)
Trial: 15283825
Drug: Rectal paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal paracetamol (20‐25 mg x kg(‐1)) preoperatively
Trial: 15283825
Drug: Rectal paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal paracetamol (20‐25 mg x kg(‐1)) postoperatively
Trial: 8386917
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg nedocromil sodium four times daily for 12 weeks
Trial: 3122518
Drug: Mannitol administered
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol administered 30 min prior to bypass
Trial: 31977698
Drug: Submandibular anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submandibular anesthesia through catheter perfusion, lingual nerve block, and subcutaneous infiltration anesthesia
Trial: 31977698
Drug: Lingual nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lingual nerve block and subcutaneous infiltration anesthesia
Trial: 30132686
Drug: Pediatric Prolonged-Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric Prolonged-Release Melatonin (PedPRM) 2/5 mg nightly for 39 weeks
Trial: 24198051
Drug: Atorvastatin (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (5-10 mg for 3 months)
Trial: 24198051
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg for 3 months)
Trial: 22510898
Drug: Autologous platelet‐leukocyte‐enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet‐leukocyte‐enriched plasma spray
Trial: 20149066
Drug: Experienced Community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experienced Community Oral Health Workers (COHW)
Trial: 15205717
Drug: Atorvastatin, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin, 20 mg per day (n=24)
Trial: 11723148
Drug: 125‐mg b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125‐mg b.i.d. doses of levodopa/benserazide (Madopar)
Trial: 8267134
Drug: Haloperidol treatment
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol treatment (plasma levels varied, duration 6 weeks)
Trial: 17661330
Drug: Echinacea purpurea
RxNorm normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea purpurea (daily use for at least 7 days)
Trial: 11050634
Drug: High-viscosity ferristene
RxNorm normalized name: Mineral Oil (high Viscosity)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-viscosity ferristene formulations
Trial: 9329701
Drug: Propentofylline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propentofylline (3 x 300 mg taken 1 hr before food)
Trial: 3564873
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine (0.25%) continuously administered by infusion pump, 4‐6 ml h‐1, for 48 h
Trial: 3564873
Drug: Epidural morphine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine, 2‐6 mg, at the end of operation and repeated on the first and second postoperative mornings
Trial: 3564873
Drug: Epidural morphine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine, 2‐6 mg per die, administered for 48 h continuously by infusion pump
Trial: 3564873
Drug: Intramuscular oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular oxycodone (0.15 mg kg‐1) on request
Trial: 25011643
Drug: Thrombin-based topical
RxNorm normalized name: thrombin Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombin-based topical haemostatic agent (Floseal)
Trial: 23442748
Drug: Screening and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening and treatment of asymptomatic carriers with artemether-lumefantrine during community screening campaigns.
Trial: 23442748
Drug: Screening and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening and treatment of asymptomatic carriers with artemether-lumefantrine during campaign 1.
Trial: 23442748
Drug: Screening and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening and treatment of asymptomatic carriers with artemether-lumefantrine during campaigns 2 and 3.
Trial: 23442748
Drug: Screening and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening and treatment of asymptomatic carriers with artemether-lumefantrine during campaign 4.
Trial: 12671888
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone 200 mg
Trial: 10846910
Drug: Urapidil (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (0.4 mg/kg)
Trial: 8401358
Drug: Propantheline 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propantheline 30 mg orally every 6 h for six doses
Trial: 29909565
Drug: Topical pimecrolimus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pimecrolimus, applied four times daily for 4 weeks
Trial: 29909565
Drug: Betamethasone cream,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone cream, applied four times daily for 4 weeks
Trial: 27462136
Drug: Alprazolam 0.5
RxNorm normalized name: alprazolam 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.5 mg daily for two weeks
Trial: 25169639
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for benign struma ovarii (25 cystectomies, 15 unilateral salpingo-oophorectomies, 2 bilateral salpingo-oophorectomies, 22 hysterectomies with salpingo-oophorectomy)
Trial: 25169639
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for malignant struma ovarii (1 fertility-sparing staging surgery, 2 unilateral salpingo-oophorectomies, 1 hysterectomy with bilateral salpingo-oophorectomy)
Trial: 25169639
Drug: Chemotherapy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy after surgery for malignant struma ovarii (2 patients)
Trial: 15753235
Drug: Modafinil (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (400 mg x 1)
Trial: 6806155
Drug: Intravenous mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous mannitol (1 g/kg)
Trial: 6806155
Drug: Dexamethasone (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (32 mg stat, 8 mg qds)